

# ***Shivani Satish Wagh***

---

**February 28, 2024**

To,  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai – 400 001  
**Scrip Code - 543434**

To,  
**National Stock Exchange of India Ltd**  
Exchange Plaza, Plot No. C/1, G block,  
Bandra-Kurla Complex,  
Bandra (E), Mumbai – 400 051  
**Scrip ID – SUPRIYA**

**Sub: Disclosure under Regulation 10(6) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.**

**Ref.: Prior intimation submitted under Regulation 10(5) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 dated December 19, 2023.**

**Dear Sir / Madam,**


With regard to the captioned subject and in continuation to my prior intimation submitted under Regulation 10(5) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 dated December 19, 2023, please find enclosed herewith the disclosure under Regulation 10(6) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 with respect to the acquisition of 73,125 (Seventy Three Thousand One Hundred and Twenty-Five) equity shares of Supriya Lifescience Limited (Target Company) from Dr. Saloni Satish Wagh, member of Promoter group Whole Time Director of Target Company, details of which are enclosed herewith.

The said acquisition is pursuant to off market inter-se transfer of shares between member of Promoter Group (immediate relatives), as specified in Regulation 10(1)(a)(i) and (ii) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 by way of Gift.

This is for your kind information and record.

Thanking you,

Yours faithfully,

  
**Shivani Satish Wagh**  
**Acquirer & member of Promoter Group**

Encl: As above

**CC:**  
**The Company Secretary**  
**Supriya Lifescience Limited**  
207/208, Udyog Bhavan, Sonawala Road,  
Goregaon (East), Mumbai – 400 063.

Disclosures under Regulation 10(6) –Report to Stock Exchanges in respect of any acquisition made in reliance upon exemption provided for in Regulation 10 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011			
1.	Name of the Target Company (TC)	Supriya Lifescience Limited	
2.	Name of the acquirer(s)	Shivani Satish Wagh	
3.	Name of the stock exchange where shares of the TC are listed	1. BSE Limited 2. National Stock Exchange of India Limited	
4.	Details of the transaction including rationale, if any, for the transfer/ acquisition of shares.	Transfer of 73,125 Equity Shares i.e. 0.09% of total share capital as per the latest shareholding pattern of the TC from Dr. Saloni Satish Wagh to Ms. Shivnai Satish Wagh. (Ms. Shivnai Satish Wagh is the sister of Dr. Saloni Satish Wagh).  Inter-se transfer of shares amongst member of Promoter Group (immediate relatives) without consideration by way of Gift.	
5.	Relevant regulation under which the acquirer is exempted from making open offer.	Under Regulation 10(1)(a)(i) and (ii) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011	
6.	Whether disclosure of proposed acquisition was required to be made under regulation 10 (5) and if so, - whether disclosure was made and whether it was made within the timeline specified under the regulations. - date of filing with the stock exchange.	The proposed acquisition was made under regulation 10 (5) - Intimation to Stock Exchanges in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Yes, the disclosure was made within the timeline specified under the regulations. The same was filed on 19.12.2023 with stock exchanges.	
7.	Details of acquisition	Disclosures required to be made under regulation 10(5)	Whether the disclosures under regulation 10(5) are actually made
a.	Name of the transferor / seller	Dr. Saloni Satish Wagh	Yes
b.	Date of acquisition	26.02.2024	Yes
c.	Number of shares/ voting rights in respect of the acquisitions from each person mentioned in 7(a) above	73,125	Yes
d.	Total shares proposed to be acquired / actually acquired as a % of diluted share capital of TC	0.09% of total share capital as per the latest shareholding pattern of the TC	Yes
e.	Price at which shares are proposed to be acquired / actually acquired	Not Applicable (Inter se transfer of shares among the Promoter Group without consideration by way of Gift)	Yes



8.	Shareholding details	Pre-Transaction		Post-Transaction	
		No. of shares held	% w.r.t total share capital of TC	No. of shares held	% w.r.t total share capital of TC
	a Each Acquirer / Transferee(*) along with PAC				
	Ms. Shivani Satish Wagh	29,250	0.04	1,02,375	0.13
	Dr. Satish Waman Wagh	5,44,41,205	67.64	5,44,41,205	67.64
	Mrs. Smita Satish Wagh	3,21,750	0.40	3,21,750	0.40
	Supriya Pharmaceuticals	10	0.00	10	0.00
	b Each Seller / Transferor				
	Dr. Saloni Satish Wagh	1,75,500	0.22	1,02,375	0.13
	<b>Total</b>	<b>5,49,67,715</b>	<b>68.30</b>	<b>5,49,67,715</b>	<b>68.30</b>

Note:

(\*) Shareholding of each entity shall be shown separately and then collectively in a group.

The above disclosure shall be signed by the acquirer mentioning date & place. In case, there is more than one acquirer, the report shall be signed either by all the persons or by a person duly authorized to do so on behalf of all the acquirers.

\*\*\*\*\*



Shivani Wagh  
Acquirer